Denali Therapeutics (NASDAQ:DNLI) Price Target Lowered to $28.00 at Bank of America
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its target price reduced by Bank of America from $30.00 to $28.00 in ...
Denali Therapeutics (NASDAQ:DNLI) Trading Down 8.9% After Analyst Downgrade
Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) were down 8.9% during trading on Monday after Bank of America lowered their price target on the stock from $30.00 to $28.00. Bank of ...
Denali Therapeutics (DNLI) Receives a Buy from Bank of America Securities
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today. The company’s ...
Denali Therapeutics price target lowered to $28 from $30 at BofA
BofA lowered the firm’s price target on Denali Therapeutics (DNLI) to $28 from $30 and keeps a Buy rating on the shares. The firm updated for ...
American Association of Individual Investors2d
Why Denali Therapeutics Inc.’s (DNLI) Stock Is Down 10.43%
Denali Therapeutics Inc.’s DNLI share price has dipped by 10.43%, which has investors questioning if this is right time to buy.
Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback
Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug.